Biggest News Aggregation in the World
📰 Hartmutj Ehrlich News

Page 4 - Hartmutj Ehrlich News Today

Fast, Ad-Free News Updates

Stay updated with breaking news from Hartmutj Ehrlich. Real-time updates on events, politics, business and more.

Abivax publishes novel data with respect to obefazimod's anti-inflammatory mechanism of action

EQS-News: ABIVAX / Key word(s): Scientific publicationAbivax publishes novel data with respect to obefazimod’s anti-inflammatory mechanism of action 05.01.2023 / 08:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax publishes novel data with respect to obefazimod’s anti-inflammat...
France General Hartmutj Ehrlich Enregistrement Universel Distribution Services Translational Gastroenterology Euronext Paris

Abivax receives FDA agreement on pediatric development plan with obefazimod in IBD

EQS-News: ABIVAX / Key word(s): StudyAbivax receives FDA agreement on pediatric development plan with obefazimod in IBD 20.12.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.Abivax receives FDA agreement on pediatric development plan with obefazimod in IBDThe FDA agreed on...
France General Hartmutj Ehrlich Enregistrement Universel Drug Administration Distribution Services Pediatric Study Plan

Stay Updated with Latest News

Get breaking news updates delivered to your inbox

Browse All News →

Abivax to attend the J.P. Morgan 41st Annual Healthcare Conference

EQS-News: ABIVAX / Key word(s): ConferenceAbivax to attend the J.P. Morgan 41st Annual Healthcare Conference 14.12.2022 / 18:00 CET/CESTThe issuer is solely responsible for the content of this announcement.ABIVAX TO ATTEND THE J.P. MORGAN 41ST ANNUAL HEALTHCARE CONFERENCEAbivax’s senior executive management wil...
United States France General San Francisco Hartmutj Ehrlich Enregistrement Universel Francis Drake

First US patient enrolled in Abivax's phase 3 trial of obefazimod for ulcerative colitis

Abivax announced that the first U.S. patient has been enrolled in its global phase 3 clinical trial of its oral small-molecule inhibitor obefazimod for the treatment of moderate to severe ulcerative colitis. The trial will include two induction studies – ABTECT-1 (ABX464-105) and ABTECT-2 (ABX464-106) – and a subsequent ABTECT maintenance trial (ABX464-107) that will investigate 25
Hartmutj Ehrlich Brucee Sands Henryd Janowitz Robert Stott Icahn School Of Medicine At Mount Sinai Icahn School
Source: healio.com

Explore More Categories

World News India News Business Technology Sports Entertainment Health Science